Literature DB >> 8148496

Reactivation of hepatitis B virus in two chronic GVHD patients after transplant.

P M Chen1, S Fan, J H Liu, T J Chiou, S R Hsieh, R S Liu, C H Tzeng.   

Abstract

We report two cases of hepatitis B virus reactivation following allogeneic bone marrow transplantation (BMT) for severe aplastic anemia and acute myelocytic leukemia. The presence of antibodies to HBsAg, HBeAg and HBcAg prior to transplant indicated previous infection with hepatitis B virus (HBV). These antibodies disappeared 2 and 4 months after the onset of chronic graft versus host disease (GVHD) following immunosuppressive treatment, but HBsAg reappeared in their sera 6 and 10 months later, respectively. This suggests that chronic GVHD and immunosuppressive drugs can reactivate HBV in HBsAb-positive patients, most likely because of the decrease in quality and function of helper T cells and B cells during chronic GVHD to induce clearance of HBV antibodies and reactivation of HBV. Our observation confirms that patients with HBsAb, HBeAb and HBcAb present in their sera should not be considered to have 'immunity' to HBV after BMT.

Entities:  

Mesh:

Year:  1993        PMID: 8148496

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

1.  Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation.

Authors:  H Sakamaki; Y Sato; S I Mori; K Ohashi; S Tanikawa; H Akiyama; T Sasaki; K Hiruma
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

2.  Differences in liver pathology and clinical outcome between two patients with hepatitis B virus and graft versus host disease.

Authors:  C Ustün; M Ozcan; G Gürman; M Cakir; S Erekul; G Akyol; M Arat; H Celebi; R Idlman; O Ilhan; T Demirer; M Beksac; H Koc
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

3.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

4.  Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation.

Authors:  Quan Le; Aarthi Shenoy; Eleftheria Koklanaris; Richard Childs; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2009-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.